San Diego CA— Lysulin, Inc. announced today another patent approval for their flagship product Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes. Lysulin provides a breakthrough approach for blood glucose management in an all-natural product available over the counter, without a prescription, at low cost.
Lysulin’s approved patent is the fifth patent secured for the company, for its method of preventing protein glycation using a supplement. Protein glycation is the cause of insulin resistance and type 2 diabetes and its complications. Lysulin acts like a sponge to remove glucose from the bloodstream before it can cause harm.
In a published double-blind, placebo-controlled clinical study, substantial reductions in Hemoglobin A1c (A1c) test levels were observed in people taking Lysulin as compared to people taking a placebo. Improved insulin resistance and beta cell function were also observed.
Dr. John F. Burd, CEO of Lysulin, Inc., says, “This patent is an important addition to our patent portfolio to protect our unique formulation.”
Dr. Burd was the founder and first CEO of DexCom and is renowned for his work in the medical and biotechnology field. He was inducted into the American Association of Clinical Chemistry (AACC) Hall of Fame in 2005 after winning the Ullman prize for innovation in clinical chemistry.
Lysulin is available without a prescription and can be purchased at http://www.lysulin.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.